POLYMED Poly Medicure Q3 FY25 results (Oct–Dec 2024) and concall
Poly Medicure delivered a robust Q3 FY25 performance characterized by strong double-digit revenue growth and margin expansion. The company is successfully diversifying its portfolio into high-margin segments like cardiology and oncology while maintaining leadership in infusion therapy. With a massive cash reserve from its QIP, the company is embarking on a significant CAPEX cycle to build three new plants, aiming to sustain a 'new normal' growth rate of 20% plus.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 420 | 424 |
| EBITDA | 115 | 114 |
| Net profit | 87 | 85 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
